Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.57 |
| ▸ | CES1 | P23141 | 3/20 | 0.57 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706029 | 0.82 | HPGD (0.46) | CES2CES1ALDH1A1KMT2ARAB9A | |
| SCHEMBL28142648 | 0.81 | CES2 (0.57) | CES2CES1ACKR3L3MBTL1ALDH1A1 | |
| SCHEMBL6605209 | 0.79 | POLB (0.37) | CES2CES1RAB9A | |
| SCHEMBL8975156 | 0.77 | CES2 (0.54) | CES2CES1ALDH1A1KMT2ARAB9A | |
| SCHEMBL6604112 | 0.76 | CES2 (0.55) | CES2CES1ALDH1A1 | |
| Acetonitrile SCHEMBL27854605 | 0.74 | CES2 (0.57) | CES2CES1L3MBTL1ALDH1A1HTT | |
| SCHEMBL11570 | 0.74 | CES2 (0.68) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL30954392 | 0.74 | CES2 (0.68) | CES2CES1L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL29372550 | 0.74 | CES2 (0.68) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL13291390 | 0.73 | CES2 (0.74) | CES2CES1L3MBTL1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2170337-A1 | NOVEL TRIAZOLOPYRIDAZINES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1102757-B1 | SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS | GLAXO GROUP LTD (GB) | 2004-04-14 | — | — | EP | disclosed |
| US-6498174-B1 | AGONISTS TO PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; MODULATING BLOOD GLUCOSE AND LIPID LEVELS; REDUCING DYSLIPIDEMIA AND HYPERINSULINEMIA ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE OR METABOLIC SYNDROME | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | CES2 2517/4885CES1 1409/4885ACKR3 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.